During the last session, Vera Therapeutics Inc (NASDAQ:VERA)’s traded shares were 0.61 million, with the beta value of the company hitting 1.17. At the end of the trading day, the stock’s price was $28.82, reflecting an intraday loss of -1.64% or -$0.48. The 52-week high for the VERA share is $51.61, that puts it down -79.08 from that peak though still a striking 9.82% gain since the share price plummeted to a 52-week low of $25.99. The company’s market capitalization is $1.82B, and the average trade volume was 825.43K shares over the past three months.
Vera Therapeutics Inc (VERA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.15. VERA has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.77.
Vera Therapeutics Inc (NASDAQ:VERA) trade information
Vera Therapeutics Inc (VERA) registered a -1.64% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.64% in intraday trading to $28.82, hitting a weekly high. The stock’s 5-day price performance is -3.71%, and it has moved by -24.38% in 30 days. Based on these gigs, the overall price performance for the year is -36.17%.
The consensus price target of analysts on Wall Street is $34, which implies an increase of 15.24% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $38 respectively. As a result, VERA is trading at a discount of -31.85% off the target high and 79.18% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 4.49%. While earnings are projected to return -14.38% in 2025, the next five years will return 7.46% per annum.
VERA Dividends
Vera Therapeutics Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 3.62 million shares, is of PRICE T ROWE ASSOCIATES INC /MD/’s that is approximately 7.1022% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $130.98 million.
Also, the Mutual Funds coming in first place with the largest holdings of Vera Therapeutics Inc (VERA) shares are Price (T.Rowe) New Horizons Fund and Vanguard Total Stock Market Index Fund . Data provided on Dec 31, 2024 indicates that Price (T.Rowe) New Horizons Fund owns about 1.57 shares. This amounts to just over 2.47 percent of the company’s overall shares, with a $45.34 million market value. The same data shows that the other fund manager holds slightly less at 1.33, or about 2.09% of the stock, which is worth about $38.35 million.
